Spruce Biosciences Inc, a late-stage biopharmaceutical company dedicated to advancing novel treatments for neurological disorders with high unmet medical need, has appointed Keli Walbert to its Board of Directors. The company is focused on progressing therapies that have the potential to significantly improve outcomes for patients with rare and complex conditions.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 5 December 2025
Michael Grey, Executive Chairman of Spruce Biosciences, said that Walbert’s appointment comes at a critical point in the company’s evolution as it moves closer to submitting a Biologics License Application for TA-ERT, a potential treatment for Sanfilippo Syndrome Type B, also known as MPS IIIB. He noted that her track record of leading successful product launches and her deep experience in rare disease commercialization will be valuable as Spruce prepares to operate as a commercial-stage organization. Grey added that her perspective will help guide the company as it works toward delivering what could become the first disease-modifying therapy for children affected by MPS IIIB.
Health Technology Insights: Daiichi Sankyo Highlights ADC Breast Cancer Trial Updates
Walbert brings more than two decades of experience across a wide range of commercial leadership roles, including marketing, sales, market access, patient support programs, advocacy, digital strategy, analytics, and operational management. Her therapeutic background spans immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology, and metabolic and obesity-related diseases. She is particularly well known for her expertise in building and scaling commercial strategies for rare disease therapies.
Most recently, Walbert served as Executive Vice President of U.S. Commercial at Horizon Therapeutics. In that role, she led commercial strategy and organizational growth for more than ten marketed products across multiple therapeutic areas, including nephrology, ophthalmology, and rare diseases. During her tenure at Horizon, she also played a key role in the launch of TEPEZZA, a breakthrough treatment for thyroid eye disease. Earlier in her career, she held senior leadership positions at AbbVie, the American Medical Association, Abbott, and United Healthcare, gaining broad experience across healthcare, pharmaceuticals, and payer organizations.
Her contributions to the industry have been recognized with several honors, including the Luminary Award from the Healthcare Businesswomen’s Association and the MM+M Women of Distinction Award. Walbert holds a master’s degree from Northwestern University and a bachelor’s degree from the University of Louisville.
Commenting on her appointment, Walbert said she is joining the Spruce Biosciences Board at a moment of strong momentum as the company advances toward a potential BLA submission for TA-ERT. She shared that she looks forward to collaborating with the Board and leadership team to support commercial planning efforts and help position the company for what could be a pivotal year of transformation and growth.
Health Technology Insights: How LG Is Moving Into Clinical Workflows
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
